Erythropoietic protoporphyria (EPP) is Clinuvel's lead clinical indication for its drug SCENESSE® (afamelanotide).
This webpage is a portal for all information relevant to clinical studies and news relevant to EPP.
SCENESSE® is currently available by prescription to Italian citizens diagnosed with EPP (learn more here). Clinuvel has filed a marketing authorisation application for SCENESSE® for EPP with the European Medicines Agency (read more here). The company is currently awaiting further feedback from the FDA on the direction of its US EPP program.
